<DOC>
	<DOCNO>NCT00557596</DOCNO>
	<brief_summary>This open-label multicenter , phase 1-2 study . Following determination recommend AEG35156 dose combination gemcitabine initial Phase 1 part study , additional patient enrol Phase 2 part study ass activity combination first-line advance pancreatic cancer .</brief_summary>
	<brief_title>A Phase 1-2 , XIAP Antisense AEG35156 With Gemcitabine Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Apoptotic induction cancer cell seek therapeutic goal . Most successful anticancer agent activate apoptosis pathway cancer treat . Apoptotic pathway cell appear converge single family enzyme , caspase , proteases dismantle cell orderly , non-inflammatory fashion , result cell death . The X-linked Inhibitor Apoptosis ( XIAP ) know cellular inhibitor caspase , expression thereby block principal mean apoptosis . A wide range evidence indicate cellular overexpression member IAP family fundamental mean many cancer cell evade death , even presence strong extrinsic ( death receptor-mediated ) intrinsic ( mitochondria-mediated ) apoptotic cue . The inhibition cellular XIAP activity , specifically cancer cell stress prim apoptosis chemotherapeutic agent , view powerful mean tip balance towards cell death . In particular , XIAP show overexpressed pancreatic cancer play important role gemcitabine resistance . AEG35156 second generation antisense target XIAP mRNA low XIAP level apoptotic threshold cancer cell , enhance sensitivity intrinsic death chemotherapy . AEG35156 may thus enhance anticancer activity gemcitabine patient advance pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>X-Linked Inhibitor Apoptosis Protein</mesh_term>
	<criteria>Patients histologically cytologically confirm advanced pancreatic adenocarcinoma candidate firstline gemcitabine therapy Karnofsky performance &gt; 70 % One metastatic tumor measurable RECIST criterion CT scan MRI ( Phase 2 part ) Life expectancy least 3 month Age &gt; 18 year Signed , write IRBapproved informed consent A negative serum pregnancy test ( applicable ) Acceptable liver function : Bilirubin &lt; 1.5 time institution 's upper limit normal AST ( SGOT ) , ALT ( SGPT ) Alkaline phosphatase &lt; 2.5 time institution 's upper limit normal Acceptable renal function : Serum creatinine within normal limit , OR calculate creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal Acceptable hematologic status : Granulocyte &gt; 1500 cells/uL Platelet count &gt; 100,000 plt/uL Hemoglobin &gt; 9.0 g/dL Acceptable coagulation status : PT within normal limit PTT within normal limit For woman childproducing potential , use effective contraceptive method study Prior radiotherapy local disease allow provided disease progression document , treatment complete least 4 week prior registration Prior chemotherapy pancreatic cancer , except 5fluorouracil gemcitabine give radiosensitizer Active progressive brain metastasis include presence relate symptom need corticosteroid . A CT MRI scan head necessary patient history brain metastasis document stability prior lesion . Known bleed diathesis concurrent treatment anticoagulant except patient nontherapeutic line maintenance coumadin Pregnant nursing woman . NOTE : Women childbearing potential must agree use adequate contraception ( sterile surgically sterile ; hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately Men unwilling use acceptable form birth control engage sexual contact woman child bear potential Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Known infection HIV , hepatitis B , hepatitis C Serious nonmalignant disease could compromise protocol objective opinion investigator and/or sponsor Patients currently receive investigational agent . Subjects use previous antisense oligonucleotide last 90 day exclude Unwillingness inability comply procedure require protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>antisense</keyword>
	<keyword>oligonucleotide</keyword>
	<keyword>gemcitabine</keyword>
</DOC>